Page 203 - DUOKOPT BIBLIOBOOK

EFFICACY/TOLERABILITY

Dovepress Tolerability and effectiveness of preservative-free dorzolamide–timolol

treatment-naïve, newly diagnosed patients with open-angle 10. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized
trial in patients inadequately controlled with timolol alone comparing
glaucoma or ocular hypertension. Future real-life studies
the dorzolamide-timolol combination to monotherapy with timolol or
assessing the relative difference in nonvisual symptoms dorzolamide. Dorzolamide-Timolol Combination Study Group. Oph-
between various glaucoma treatments and between preserved thalmology. 1998;105(10):1952–1959.
11. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability
and unpreserved formulations of dorzolamide–timolol, would of the dorzolamide 2% timolol 0.5% combination (COSOPT) versus
further contribute to the management of glaucoma. 0.005% (XALATAN) in the treatment of ocular hypertension or glau-
coma: results from two randomized clinical trials. Acta Ophthalmol
Scand. 2004;82(1):42–48.
Acknowledgments 12. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Efficacy of
the dorzolamide/timolol fixed combination versus latanoprost in the
This study was supported by Merck Frosst Canada Ltd. The
treatment of ocular hypertension or glaucoma: combined analysis of
authors would like to acknowledge the study investigators: pooled data from two large randomized observer and patient-masked
Jeffrey Chambers, David Neima, Carl Peters, Roberto LG studies. J Ocul Pharmacol Ther. 2005;21(3):242–249.
13. Francis BA, Du LT, Berke S, Ehrenhaus M, Minckler DS. Comparing
Piemontesi, Lindsay Ong-Tone, Adian Long, George Colev, the fixed combination dorzolamide-timolol (COSOPT) to concomitant
Cindy Hutnik, Fahim Ibrahim, Thomas Klein, Derek P-K administration of 2% dorzolamide (trusopt) and 0.5% timolol – a
randomized controlled trial and a replacement study. COSOPT Study
Lui, Girair Basmadijian, Rama R Behki, Serge Boucher,
Group. J Clin Pharm Ther. 2004;29(4):375–380.
François Demay, Stephen H Fichman, Clovis Eid, Robert 14. Gandolfi SA, Rossetti L, Cimino L, Mora P, Tardini M, Orzalesi N.
Scott. Replacing maximum-tolerated medications with latanoprost versus
adding latanoprost to maximum-tolerated medications: a two-center
Trial registration number: This study is registered at randomized prospective trial. J Glaucoma. 2003;12(4):347–353.
clintrial.gov: NCT # 000545064. 15. Henderer JD, Wilson RP, Moster MR, et al. Timolol/dorzolamide
combination therapy as initial treatment for intraocular pressure over
30 mmHg. J Glaucoma. 2005;14(4):267–270.
Disclosures 16. Hutzelmann J, Owens S, Shedden A, Adamson I, Vargas E. Comparison
of the safety and efficacy of the fixed combination of dorzolamide/
C Hutnik, D Neima, F Ibrahim, and R Scott have no timolol and the concomitant administration of dorzolamide and timolol:
competing financial interests to declare. N Bastien and a clinical equivalence study. International Clinical Equivalence Study
S Foucart are employees of Merck Frosst Canada Ltd; Group. Br J Ophthalmol. 1998;82(11):1249–1253.
17. Konstas AG, Kozobolis VP, Tsironi S, Makridaki I, Efremova R,
J Vaillancourt, D Haine, and J Sampalis are employees of Stewart WC. Comparison of the 24-hour intraocular pressure-lowering
JSS Medical Research Inc (contract research organization); effects of latanoprost and dorzolamide/timolol fixed combination
after 2 and 6 months of treatment. Ophthalmology. 2008;115(1):
all study investigators received grants related to the conduct
99–103.
of the study. 18. Rolle T, Tofani F, Brogliatti B, Grignolo FM. The effects of dorzol-
amide 2% and dorzolamide/timolol fixed combination on retinal and
optic nerve head blood flow in primary open-angle glaucoma patients.
References Eye. 2008;22(9):1172–1179.
1. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular 19. Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD. Com-
pressure and primary open angle glaucoma among white and parison of the safety and efficacy of dorzolamide 2% and brimonidine
black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma.
1991;109(8):1090–1095. 2004;13(2):168–173.
2. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual 20. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms
impairment in the year 2002. Bull WHO. 2004;82(11):844–852. and signs with preserved and preservative free glaucoma medication.
3. Adatia FA, Damji KF. Chronic open-angle glaucoma. Review for primary Br J Ophthalmol. 2002;86(4):418–423.
care physicians. Can Fam Physician. 2005;51:1229–1237. 21. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A,
4. Lee AG, Beaver HA. Visual loss in the elderly – Part I: Chronic visual loss: Zeyen T. Ocular symptoms and signs with preserved and preservative-
what to recognize and when to refer. Clin Geriatr. 2003;11(6):46–53. free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341–349.
5. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma 22. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface
and ocular hypertension: implications for patient management: a review. disease in glaucoma patients J Glaucoma. 2008;17(5):350–355.
Drugs Aging. 2005;22(4):315–321. 23. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry
6. Damji KF, Behki R, Wang L. Canadian perspectives in glaucoma man- eye syndrome Arch Ophthalmol. 2000;118(9):1264–1268.
agement: setting target intraocular pressure range. Target IOP workshop 24. Lee BL, Gutierrez P, Gordon M, et al. The glaucoma symptom scale.
participants. Can J Ophthalmol. 2003;38(3):189–197. A brief index of glaucoma-specific symptoms. Arch Ophthalmol.
7. Frampton JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% 1998;116(7):861–866.
ophthalmic solution: a review of its use in the treatment of glaucoma 25. Canadian Ophthalmological Society. Evidence-based clinical practice
and ocular hypertension. Drug Aging. 2006;23(12):977–995. guidelines for the management of glaucoma in the adult eye. Can J
8. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial Ophthalmol. 2009;44 Suppl 1:S7–S93.
comparing the dorzolamide-timolol combination given twice daily to 26. Baudouin C. Detrimental effect of preservatives in eyedrops:
monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study implications for the treatment of glaucoma. Acta Ophthalmol.
Group. Ophthalmology. 1998;105(10):1945–1951. 2008;86(7):716–726.
9. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol 27. Chawla A, McGalliard JN, Batterbury M. Use of eyedrops in glaucoma:
combination versus the concomitant drugs. Am J Ophthalmol. how can we help to reduce non-compliance? Acta Ophthalmol Scand.
2000;130(6):832–833. 2007;85(4):464.

Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com 589 203
Dovepress